Lenvatinib Synthon

Lenvatinib, the active ingredient in Lenvatinib Synthon, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It targets multiple receptor tyrosine kinases and is indicated for differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma in adult patients.

GNH USA supplies Lenvatinib Synthon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenvatinib acts on several receptor tyrosine kinases involved in tumor angiogenesis and cell proliferation, making it useful in specific solid‑tumor cancers.

- Differentiated thyroid cancer: improves progression‑free survival in patients with radioactive‑iodine refractory disease. - Renal cell carcinoma: reduces tumor growth in advanced clear‑cell RCC. - Hepatocellular carcinoma: delays disease progression in patients with unresectable HCC.

Lenvatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypertension: elevated blood pressure requiring monitoring. - Diarrhea: may be mild to moderate. - Fatigue: persistent tiredness. - Decreased appetite: reduced food intake. - Nausea: occasional upset stomach. - Proteinuria: presence of protein in urine.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury. - Arterial thromboembolism: risk of clot formation. - Severe hemorrhage: significant bleeding events. - Gastrointestinal perforation or fistula formation. - Cardiac dysfunction: reduced heart function. - Life‑threatening infections.

Before initiating therapy, clinicians should evaluate several safety parameters.

- Monitor blood pressure: check regularly and treat hypertension promptly. - Assess liver function: obtain baseline tests and repeat periodically. - Evaluate renal function: monitor creatinine and proteinuria. - Consider pregnancy risk: category D; avoid use in pregnant women and advise effective contraception. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lenvatinib can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase lenvatinib exposure and toxicity. - Anticoagulants: heightened risk of bleeding. - Live vaccines: potential for reduced immune response.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers: may lower lenvatinib levels. - Diuretics: can affect blood pressure control. - Concomitant antihypertensives: may require dose adjustment.